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Abstract: Background: Glutamate system is modified by ethanol and contributes both to 
the euphoric and the dysphoric consequences of intoxication, but there is now growing 
evidence that the glutamatergic system also plays a central role in the neurobiology and 
treatment of mood disorders, including major depressive disorders and bipolar disorders. 
We speculate that, using acamprosate, patients with bipolar depression (BIP-A) can take 
advantage of the anti-glutamate effect of acamprosate to “survive” in treatment longer  
than peers suffering from non-bipolar depression (NBIP-A) after detoxification.  
Method: We retrospectively evaluated the efficacy of a long-term (six-month) acamprosate 
treatment, after alcohol detoxification, in 41 patients (19 males and 22 females), who could 
be classified as depressed alcoholics, while taking into account the presence/absence of 
bipolarity. Results: During the period of observation most NBIP-A patients relapsed, 
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whereas a majority of BIP-A patients were still in treatment at the end of their period of 
observation. The cumulative proportion of ‘surviving’ patients was significantly higher in 
BIP-A patients, but this finding was not related to gender or to other demographic or 
clinically investigated characteristics. The treatment time effect was significant in both 
subgroups. The treatment time-group effect was significant (and significantly better) for 
bipolar patients on account of changes in the severity of their illness. Limitations: 
Retrospective methodology and the lack of DSM criteria in diagnosing bipolarity. 
Conclusions: Bipolarity seems to be correlated with the efficacy of acamprosate treatment 
in inducing patients to refrain from alcohol use after detoxification (while avoiding 
relapses) in depressed alcoholics. Placebo-controlled clinical trials are now warranted to 
check the validity of this hypothesis. 
Keywords: acamprosate; depression; bipolarity; long-term outcome; glutamate 
 
1. Introduction 
Glutamate is the primary excitatory neurotransmitter in the brain. Glutamatergic systems are targets 
for the actions of ethanol via its antagonism towards the N-methyl-D-aspartate (NMDA) subtype of the 
glutamate receptor and other mechanisms. The modulation of glutamatergic function by ethanol 
contributes both to the euphoric and the dysphoric consequences of ethanol intoxication [1,2].  
In the last few decades, glutamate has been studied as a neurotransmitter that could play a central role 
in the processes underlying the development and maintenance of addiction. These processes include 
reinforcement, sensitization, habit learning and reinforcement learning, context conditioning, craving 
and relapse [3]; this supports the idea that alcoholism could be considered another member of the 
expanding family of glutamate-related neuropsychiatric disorders. As mentioned above, ethanol interferes 
with glutamatergic neurotransmission, one acute effect being the inhibition of NMDA receptors. 
Prolonged inhibition of these receptors by ethanol results in the development of supersensitivity;  
acute removal of ethanol causes a marked increase in the activity of postsynaptic neurons, such as those in 
the noradrenergic system, and, to an extreme degree, glutamate-induced excitotoxicity [4].  
Acting as the major excitatory neurotransmitter in the cerebral cortex, glutamate is thought to play a 
role in major mental disorders, including major depressive disorders and bipolar disorders [5–9]. 
Several studies report an increase in the level of glutamate during mania. The overexpression of the 
glutamatergic system in brain regions such as the dorsolateral prefrontal cortex (with special reference 
to left-sided structural and metabolic abnormalities) during manic phases could function as a link 
between glutamate and excitement [10,11]. In mania, there is a probable correlation between excessive 
glutamatergic neurotransmission driven by neuronal activity, and phenomena such as racing thoughts, 
distractibility, irritability and insomnia [12]. In line with these observations, in non-manic people the 
glutamine/glutamate ratio, an index that successfully captures the brain glutamatergic activity, has been 
found to be lower [13]. 
Although the relationship between substance abuse and bipolar disorder is complex and not yet 
fully understood, the idea that they could share mechanisms of self-renewal and positive mutual 
Int. J. Environ. Res. Public Health 2014, 11 12985 
 
 
reinforcement has already been raised [14–20]. A common background to these two psychopathological 
entities seems to be impulsivity which, together with excitement, appears to be the triggering and 
reinforcing factor for the continuing use of drugs in bipolar patients [21,22]. Risk-taking behaviours 
during hypomanic states are broadly recognized as being an integral part of bipolar illness [23].  
Given the fact that alcoholism is more frequent in bipolar than unipolar patients, heavy drinking is 
fairly common when patients are hypomanic [23,24]. Moreover, in bipolar patients, familial diathesis 
for mania is significantly associated with alcohol and other drugs of abuse.  
We speculate that, by using acamprosate, patients with bipolar depression can take advantage of the 
anti-glutamate effect of acamprosate to stay in treatment for a longer time than peers with non-bipolar 
depression after detoxification. This hypothesis implies that acamprosate would be able to reduce the 
drive to drink with the outcome that their time to relapse would be longer that of peers without bipolar 
depression after detoxification.  
In our clinical practice, we started considering bipolarity in all alcoholic depressed patients treated 
with acamprosate. The main aim of the present study was to retrospectively evaluate the efficacy of a 
long-term (six-month) acamprosate treatment in depressed alcoholics, dividing those showing 
bipolarity from those without bipolarity, after alcohol detoxification, with reference to the  
following parameters:  
• Total Alcohol Consumption (TAC). 
• Time to relapse, measured in days. We consider a “relapse” to have taken place if a male 
patient takes more than 2 drinks on one day or if a female patient takes more than 1 drinks on 
one day (expressed in terms of standard US drinks; one standard U.S. drink = 14 g absolute 
alcohol) [25]; we do not consider patients as having relapsed if there has only been a “slip”, 
which can be defined as an occasion when a male patient takes no more than 2 drinks on one 
day or when a female patient takes 1 drink on one day. With this kind of outcome, of course, 
we did not consider that there had been a “relapse into heavy drinking days” (relapse-HDD), 
which happens when a male patient takes 5 or more drinks on a single day or a female patient 
takes 4 or more drinks on a single day [25]. 
• Clinical Global index (CGI). 
• Global functioning assessment (GAF). 
• Time in days with TAC = 0. 
The secondary aim was to evaluate the correlation between demographic, clinical variables and 
retention in treatment. 
2. Experimental Section  
2.1. Sample  
We retrospectively considered all consecutive depressed chronic alcoholics in treatment with 
acamprosate at the Dual Diagnosis Unit of the Department of Psychiatry of the University of Pisa, 
Italy, during a three-year period, 2010–2013. The inclusion criteria were: 
• Diagnosis of alcohol dependence according to DSM-IV-R criteria [26]. 
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• Diagnosis of major depressive episode according to DSM-IV-R criteria. 
• Presence of multiple psychosocial or environmental problems within the previous two years. 
• Patients consuming over 5 units of alcohol per day at treatment entry. 
• Patients living with their families. 
• Having successfully accomplished 7 days of a detoxification program with sodium oxybate.  
• Having successfully recovered from a depressive state after 3 weeks, whether using or not 
using serotoninergic agents (if used, serotoninergic agents were prescribed for a short period of 
time, at most 3 weeks). 
• Patients not treated with antiepileptics. 
Exclusion criteria were: 
• Serious liver disorders and chronic diseases. 
The sample consisted of 41 patients, 19 (46.3%) of them males and 22 (53.7) females, average age 
40.88 ± 11.5 (min 17, max 66). Patients were mostly involved in a stable sexual relationship  
(n = 25; 65.8%), and were currently blue collar (n = 26; 65.0%), with a low educational level  
(n = 24; 64.9%), without welfare benefits (n = 34; 85.0%), with adequate income (n = 35; 92.1%),  
but experiencing difficulties as to social adjustment, and living in a family (n = 33; 80.5%).  
According to the Hypomania Check-List (HCL) cut-off, 22 patients showed a depressive episode in the 
absence of bipolar spectrum (NBIP-A patients). 11 (50.0%) were males, age ranged between 26 and  
38 years (average age 43.50 ± 10.9). 19 were affected by bipolar depression (HCL score ≤ 14)  
(BIP-A patients). 8 (42.6%) were males, age ranged between 17 and 66 years (average age 37.84 ± 11.8).  
2.2. Instruments  
The following instruments were used to collect data on the variables to be studied:  
• Demographic data (at the beginning of treatment). We considered gender (males, females),  
age (≤40 years, ≥40), education (≤8 years, ≥8 years), marital status (single, married), job status 
(white collars, blue collars, unemployed), income (poor, adequate). 
• Bipolar spectrum. To divide our sample into patients with and without bipolar spectrum,  
we used the Hypomania Check-List (HCL) compiled by Angst [27,28]. This is a checklist of  
32 possible symptoms of hypomania that are rated “yes” (present or typical of me) or “no”  
(not present or not typical) by the subject. The cut-off for the discrimination between unipolar 
and bipolar patients is fixed at a score of 14/32. 
• Alcohol intake (according to scheduled visits). This was evaluated in terms of units of alcohol. 
The easiest way to calculate this is to count the number of glasses of alcoholic drinks consumed 
daily, expressed as standard US drinks (one standard U.S. drink = 14 g absolute alcohol) [25]. 
• TAC = 0 (according to scheduled visits). This parameter was assessed through self-evaluation, 
and confirmed by family observer evaluation. One or two members of the family were 
responsible for detecting the intake of the medications and patient alcohol intake.  
• Clinical Global Impressions (CGI) (monthly). Severity of illness, global improvement and 
efficacy index were evaluated by CGI [29]. Clinical Global Impressions (CGI) is an index that 
consists of three global scales (items). Two of the items—Severity of Illness and Global 
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Improvement are rated on a 7-point scale; while the third, Efficacy Index, requires an 
assessment of the interaction of therapeutic effectiveness with adverse reactions.  
• Social adjustment (monthly). This was evaluated by means of the Global Assessment of 
Functioning (GAF) [26]. The GAF reports the clinician’s judgment on the individual’s overall 
level of functioning classified as variation from the minimum (0) to the maximum (100) level. 
A researcher who had not been informed about variations in subjects’ alcohol intake administered 
the CGI and GAF. There was a preference for the researcher not to be informed because CGI and GAF 
scales are to be rated exclusively with respect to psychological, psychopathological, social and 
occupational functioning. 
2.3. Data Analysis  
Patients were assessed monthly by the use of CGI and GAF. Patients who stayed in treatment were 
assessed at the end of treatment. When patients had negative outcomes, those who gave up were 
assessed at the time of treatment interruption, this being counted as their last regular assessment,  
rather than the previous month’s. 
Depressed patients with and without bipolarity were compared for demographic and clinical aspects 
by means of the chi-square test for categorical variables, and Student’s t test for continuous variables. 
Retention in treatment was analysed by means of the survival analysis and Wilcoxon statistics to allow 
the survival curves to be compared. For the purposes of this analysis, the term “terminal event” refers 
to patients who left the treatment after a “relapse”, while “withdrawing during interval” refers to 
patients who are still in treatment at the end-point, or have decided to leave treatment for reasons 
unrelated to the treatment itself (e.g., patients moving to other towns or cities). In other words,  
we consider 2 kinds of positive outcome: the first when a patient left the treatment programme with a 
successful result (whether because abstinent or despite a “slip”) or was referred, in the same condition, 
to other programmes; the second when a patient was still in treatment, at the end-point, either as an 
abstainer, or despite a “slip”. We consider a negative outcome to have happened if a patient has “relapsed”. 
Regarding clinical global impressions and social adjustment outcomes, univariate and multivariate 
statistical procedures have been used for cross-sectional evaluation and repeated analysis of variance 
for longitudinal evaluations.  
The statistical tests were considered significant at the level of p < 0.05. We made use of the 
statistical routines of SPSS 20.0 (IBM Corp., Armonk, NY, USA). 
3. Results and Discussion 
3.1. Baseline Evaluation (at the Beginning of the Treatment)  
On the basis of the demographic information that had been collected, no differences were observed, 
at the beginning of treatment, between BIP-A and NBIP-A patients. TAC (alcohol units/day) did not 
differ between BIP-A (7.74 ± 1.6) and NBIP-A (7.73 ± 1.4) patients. No differences were observed 
either in the CGI severity of illness (BIP-A = 5.79 ± 0.7; NBIP-A = 5.73 ± 0.7), or the GAF scores 
(BIP-A = 45.00 ± 4.7; NBIP-A = 43.18 ± 5.6).  
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3.2. Relapsing and Non-Relapsing Patients  
At the end of six months, 5 (22.7%) NBIP-A and 12 (63.2%) BIP-A patients were still in treatment, 
while 17 (77.3%) NBIP-A and 7 (36.8%) BIP-A patients had relapsed. This difference was statistically 
significant (chi square 6.86, df = 1, p = 0.009). None of the patients had been dismissed for being violent; 
none had given the treatment up because of side-effects; none had been imprisoned or hospitalized.  
At the end of six months 8 (36.4%) NBIP-A and 9 (47.4%) BIP-A patients showed uninterrupted 
TAC = 0; 14 (63.6) NBIP-A and 10 (52.6%) BIP-A patients showed slips (chi-square = 0.50; df = 1;  
p = 0.476).  
3.3. Retention in Treatment  
Table 1 shows retention in treatment in our sample. The cumulative proportion of patients “surviving”  
at the end of the observational period was significantly higher in BIP-A patients. The female (0.29)  
and male (0.48) retention rates were not statistically different (Wilcoxon statistics = 2.53, df = 1,  
p = 0.111). BIP-A males showed a better retention rate (0.75) than their NBIP-A peers (0.24)  
(Wilcoxon statistics = 6.37, df = 1, p = 0.012). BIP-A females showed a better retention rate (0.16) 
than NBIP-A females (0.09) (Wilcoxon statistics = 4.77, df = 1, p = 0.029). 
Table 1. “Survival” in treatment of depressed alcoholics with and without bipolar 
spectrum, treated with acamprosate after detoxification. 
Start Time 
(Months) 
Number 
Entering 
Interval 
Number 
Withdrawing 
during 
Interval 
Number of 
Terminal 
Events 
Cumulative 
Proportion 
“Surviving” at End of 
Given Interval 
Bipolar Spectrum Bipolar Spectrum Bipolar Spectrum Bipolar Spectrum 
No Yes No Yes No Yes No Yes 
0 22 19 0 0 1 2 0.95 0.89 
1 21 17 2 0 11 0 0.43 0.89 
2 8 17 0 0 3 1 0.27 0.84 
3 5 16 0 1 1 1 0.21 0.79 
4 4 14 1 1 1 2 0.15 0.67 
5 2 11 0 0 0 1 0.15 0.61 
6 2 10 2 10 0 0 0.15 0.61 
Overall Comparison, Wilcoxon statistics = 10.231, df = 1, p = 0.001. 
3.4. End Point Evaluation  
The percentage of TAC = 0 time in days was 0.88 ± 0.1 in BIP-A and 0.89 ± 0.1 in NBIP-A patients 
(T = −0.28; p = 0.77). CGI improvement was assessed as “much improved” in BIP-A (1.79 ± 0.7) and 
NBIP-A (2.09 ± 1.3) patients (T = 0.93; p = 0.376). CGI efficacy index differed in BIP-A and NBIP-A 
patients (Table 2). 
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Table 2. Efficacy index in alcoholics with and without bipolar spectrum treated with 
acamprosate after detoxification. 
CGI Efficacy Index 
Depressed Alcoholics (N, %) 
Without 
Bipolar Spectrum 
n = 22 
With 
Bipolar Spectrum 
n = 19 
Marked therapeutic effect - No side-effects  4 (18.2%) a 7 (36.8%) a 
Marked therapeutic effect - Does not interfere 
with patients’ functioning 
2 (9.1%) a 5 (26.3%) a 
Moderate therapeutic effect - No side-effects 5 (22.7%) a 3 (15.8%) a 
Moderate therapeutic effect - Does not 
interfere with patients’ functioning 
11 (50.0%) a 4 (21.1%) b 
No therapeutic effect – No side-effects 2 (9.1%) a 2 (10.5%) a 
Each letter denotes a subset of categories whose column proportions do not differ significantly 
from each other at the 0.05 level. 
BIP-A patients reported a lower CGI severity of illness (2.41 ± 1.3) than NBIP-A patients (3.21 ± 1.5). 
Time effect (F = 132.73, df = 1, p = 0.000), and time-group effect (F = 4.79, df = 1, p = 0.035)  
were significant. Time-group differences were not related to the outcome (F = 0.75, df = 1, p = 0.392). 
BIP-A patients (61.84 ± 10.1) and NBIP-A patients (62.73 ± 13.3) did not report significantly different 
degrees of social adjustment. Time effect was significant (F = 63.55, df = 1, p = 0.000).  
Time-group effect (F = 0.25, df = 1, p = 0.620) was not significant and was not related to the outcome 
(F = 0.88, df = 1, p = 0.769). 
3.5. Correlations between Demographic, Clinical Variables and Retention in Treatment  
Using Cox regression life table statistics, stepwise forward (Wald) method, (chi-square = 11.97,  
df = 11, p = 0.365), no correlation was found between retention rate and gender, age (≤40 years,  
>40 years), education, marital status, job, income, severity of illness, social adjustment at study entry, 
or complete abstinence from alcohol.  
3.6. Medications  
In this study the following were prescribed: 
• Acamprosate: 1.332 and 1.998 g/die if body weight was less and more than 70 kg, respectively. 
• Sodium-oxybate: 100mg/kg/die, during the first 7 days as preferred detoxification procedure.  
• Antidepressant (serotoninergic): paroxetine (up to 20 mg/die), sertraline (up to 150 mg/die), 
citalopram (up to 10 mg/die), fluvoxamine (up to 200 mg/die). 
During the period of observation most NBIP-A patients relapsed, whereas most BIP-A patients 
were still in treatment at the end of the period of observation. The cumulative proportion of 
“surviving” patients was significantly higher in BIP-A patients and showed no correlation with gender 
or tother demographically or clinically investigated characteristics. Treatment time effect was 
significant regarding CGI and GAF in both subgroups. Considering differences between the two 
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groups, the treatment time effect was significant (significantly better) in BIP-A patients for a single 
parameter: CGI severity of illness. More frequently the therapeutic effect was assessed as marked in 
BIP-A patients and as moderate in NBIP-A patients. 
At the end of our period of observation, more BIP-A patients, percentagewise, were still in 
treatment, whereas a higher percentage of NBIP-A patients had relapsed. In line with this observation, 
some studies have pointed out that bipolar alcoholics had a better outcome, as assessed by drinks  
per drinking day, than depressed alcoholics after a period of observation as long as 2 years [30],  
while others argue that these differences in outcome deriving from bipolarity are present but not 
statistically significant [31]. One consideration on retention in treatment pertinent to the role of  
dual diagnosis should be borne in mind: the higher retention percentage of BIP-A patients could be  
due to the better outcome achieved by dual diagnosis patients with respect to those without  
dual diagnosis [32]. If we focus on the length of the follow-up period, other studies highlight the 
usefulness of acamprosate at 6-months follow-up [33], especially in patients motivated to have a 
treatment goal of abstinence [34] or in patients who have benefited from forms of psychosocial  
supports [35,36]. In any cases, some Authors showed acamprosate treatment over 180 days to be 
consistently more effective than placebo in maintaining abstinence and in diminishing relapse  
severity [37], while others highlighted the finding that the effectiveness of acamprosate was similar to 
that of placebo if the administration of acamprosate was started long after detoxification [38]. 
Gender is an important variable in considering differences in the prevalence, risk, and clinical 
correlates of alcoholism in bipolar illness. While the prevalence of alcohol abuse or dependence is 
higher for bipolar men than bipolar women, the risk of developing alcoholism, by comparison with the 
general population is significantly higher for bipolar women [39,40]. Despite these distinctions, within 
our sample gender did not seem to influence retention in treatment. This is in line with other studies, 
and this finding can be considered specifically true for those dependent on alcohol [41–43],  
but it could also be extended to other substance use disorders, such as dependence on heroin [44]. 
On the issue of endpoint evaluations, BIP-A patients reported a lower severity of illness than  
NBIP-A patients. Time effect and time-group effect were both significant. Moreover, time-group 
differences were unrelated to the outcome. These are notable findings, especially if one considers the 
low degree of compliance with treatments for drug addiction and for several forms of psychiatric 
disorder. Looking at outcome and retention in treatment, there are studies that have stressed the fact 
that substance use and alcohol use disorders are associated with poor clinical outcomes in patients  
who have a bipolar disorder [45–49].  
Acamprosate shows attractive features (e.g., its pharmacokinetic and safety properties), but less than 
thrilling results: negative trials have been reported as well as large meta-analyses that support the 
concept that acamprosate efficacy is limited [34,38,41,50]. One important question that arises is 
whether there is a specific subgroup of patients who respond particularly well to this medication. 
Acamprosate has proved to be most effective in acting on a hyper-glutamatergic system [51] that is 
also involved in the pathophysiology of several psychiatric diseases such as bipolar disorder and 
bipolar depression [9,52–55]. Adopting this perspective, acamprosate would be of special interest in 
alcohol-dependent bipolar disorder patients [56–58]. A randomized, placebo-controlled clinical trial of 
add-on acamprosate on mood stabilizing medication in 33 bipolar II or I disorder adults with alcohol 
dependence did not show overall differences in drinking outcomes, but acamprosate does appears to 
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confer some clinical benefit on study completers [59]. So far, however, remarkably little research has 
been carried out on the concurrent trajectories of mood symptoms and alcohol use in people with  
co-occurring bipolar disorder and alcohol use disorders, and divergent results have been reported [60–63]. 
Depression has been investigated as a predictor of relapse in alcohol use. Results from a study by 
Priscindaro et al. suggest that depressive symptoms and alcohol craving both increase the proximal 
risks of alcohol use in individuals with co-occurring bipolar and alcohol use disorders [64].  
In reviewing mood disorders as a whole, Koukopoulos and coll. suggested the need to stress the 
“primacy of mania” hypothesis: there is not only an intrinsic link between mania and depression,  
but the excitatory process of mania functions should be seen as a primary process, with depression 
being a secondary result [65]. The efficacy of anti-glutamate drugs in bipolar depression appears to be 
mediated by lowering levels of cerebral glutamate and/or glutamine, in order to prevent the 
exitotoxicity induced by excessive stimulation [66,67]. We can speculate that, in our patients,  
the antimanic effect of acamprosate, by preventing mood instability and elation, will probably reduce 
the risks of relapse into alcohol use that are induced by excitement [68]. Anti-glutamatergic 
medications appear to provide a clinically substantial antimanic, sustained mood-stabilizing effect and 
they seem to be useful tools in treating bipolar-depression by suppressing the excitement process that 
leads to mania [69]. 
4. Limitations  
This is a retrospective study, so we can only put forward a suggestion about the possible correlation 
between acamprosate and a positive outcome in bipolar alcoholics after detoxification. We decided not 
to use DSM criteria to detect bipolarity, preferring HCL because of its higher sensitivity [19,70].  
We chose “retention in treatment” as being the primary outcome. Subjects who “survive” in treatment 
are those who have dramatically decreased their alcohol intake; by contrast, patients who “die” in 
treatment are those who have relapsed rather than slipped back into alcohol use). 
5. Conclusions  
After detoxification from alcohol, BIP-A depressed patients stay in treatment longer than their 
NBIP-A depressed peers. These results highlight the fact that bipolarity seems to be significantly 
correlated with the outcome of acamprosate treatment, in terms of the percentage of depressed patients 
who refrain from alcohol use after their detoxification. Of course that placebo-controlled clinical trials 
are now warranted and required to check the validity of this hypothesis. 
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